WO2005102275B1 - Compositions et procedes d'utilisation d'inhibiteurs d'acetylcholinesterase (ace) pour traiter les troubles du systeme nerveux central chez des mammiferes - Google Patents

Compositions et procedes d'utilisation d'inhibiteurs d'acetylcholinesterase (ace) pour traiter les troubles du systeme nerveux central chez des mammiferes

Info

Publication number
WO2005102275B1
WO2005102275B1 PCT/US2005/013776 US2005013776W WO2005102275B1 WO 2005102275 B1 WO2005102275 B1 WO 2005102275B1 US 2005013776 W US2005013776 W US 2005013776W WO 2005102275 B1 WO2005102275 B1 WO 2005102275B1
Authority
WO
WIPO (PCT)
Prior art keywords
galantamine
carboxylate
salt
carboxylate salt
solution
Prior art date
Application number
PCT/US2005/013776
Other languages
English (en)
Other versions
WO2005102275A3 (fr
WO2005102275A2 (fr
Inventor
Steven C Quay
Henry R Costantino
Michael E Houston Jr
Alexis Kays Leonard
Original Assignee
Steven C Quay
Henry R Costantino
Michael E Houston Jr
Alexis Kays Leonard
Nastech Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Steven C Quay, Henry R Costantino, Michael E Houston Jr, Alexis Kays Leonard, Nastech Pharm Co filed Critical Steven C Quay
Priority to JP2007509671A priority Critical patent/JP2007534686A/ja
Priority to CA002564353A priority patent/CA2564353A1/fr
Priority to EP05758604A priority patent/EP1753397A2/fr
Priority to MXPA06012269A priority patent/MXPA06012269A/es
Publication of WO2005102275A2 publication Critical patent/WO2005102275A2/fr
Publication of WO2005102275A3 publication Critical patent/WO2005102275A3/fr
Publication of WO2005102275B1 publication Critical patent/WO2005102275B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention porte sur des méthodes et sur des compositions qui utilisent des inhibiteurs d'acéthylcholinestérase (ACE) pour prévenir et traiter des maladies et autres troubles du système nerveux central (SNC) tels que la maladie d'Alzheimer. Les inhibiteurs d'ACE sont administrés au système nerveux central de manière ciblée, par exemple par voie intranasale. Les méthodes et les compositions de cette invention génèrent des concentrations thérapeutiques d'inhibiteurs d'ACE dans un tissu ou une partie du SNC sans les désavantages, risques et effets secondaires concomitants de l'administration par voie buccale ou par injection. Les inhibiteurs d'ACE destinés à être utilisés dans cette invention sont la galantamine et divers sels et dérivés de la galantamine. Des sels de carboxylate de la galantamine (tels que le gluconate de galantamine, le lactate de galantamine, le citrate de galantamine et le glucarate de galantamine) présentent une solubilité bien supérieure comparé à d'autres formes de la galantamine telles que l'hydrobromure de galantamine.
PCT/US2005/013776 2004-04-23 2005-04-22 Compositions et procedes d'utilisation d'inhibiteurs d'acetylcholinesterase (ace) pour traiter les troubles du systeme nerveux central chez des mammiferes WO2005102275A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2007509671A JP2007534686A (ja) 2004-04-23 2005-04-22 哺乳動物において中枢神経系（ｃｎｓ）の障害を治療するための、アセチルコリンエステラーゼ（ａｃｅ）阻害剤を使用した組成物および方法
CA002564353A CA2564353A1 (fr) 2004-04-23 2005-04-22 Compositions et procedes d'utilisation d'inhibiteurs d'acetylcholinesterase (ace) pour traiter les troubles du systeme nerveux central chez des mammiferes
EP05758604A EP1753397A2 (fr) 2004-04-23 2005-04-22 Sels de galantamine, sa methode de fabrication, et composition nasale
MXPA06012269A MXPA06012269A (es) 2004-04-23 2005-04-22 Composiciones y metodos que utilizan inhibidores de acetilcolinesterasa (ace) para tratar trastornos del sistema nervioso central (cns) en mamiferos.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/831,031 US20040254146A1 (en) 2002-05-21 2004-04-23 Carboxylate salts of galantamine and their pharmaceutical use
US10/831,031 2004-04-23

Publications (3)

Publication Number Publication Date
WO2005102275A2 WO2005102275A2 (fr) 2005-11-03
WO2005102275A3 WO2005102275A3 (fr) 2006-03-30
WO2005102275B1 true WO2005102275B1 (fr) 2006-05-11

Family

ID=34972206

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/013776 WO2005102275A2 (fr) 2004-04-23 2005-04-22 Compositions et procedes d'utilisation d'inhibiteurs d'acetylcholinesterase (ace) pour traiter les troubles du systeme nerveux central chez des mammiferes

Country Status (6)

Country Link
US (2) US20040254146A1 (fr)
EP (1) EP1753397A2 (fr)
JP (1) JP2007534686A (fr)
CA (1) CA2564353A1 (fr)
MX (1) MXPA06012269A (fr)
WO (1) WO2005102275A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060035815A1 (en) * 2004-05-04 2006-02-16 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions for delivery of ribonucleic acid to a cell
GB0605337D0 (en) 2006-03-17 2006-04-26 Genomica Sau Treatment of CNS conditions
GB0709811D0 (en) * 2007-05-22 2007-07-04 Vectura Group Plc Pharmaceutical compositions
RU2470666C2 (ru) * 2008-02-28 2012-12-27 Торэй Индастриз, Инк. Фармацевтическая композиция для трансназального введения
BG110141A (en) * 2008-05-23 2009-12-31 "Софарма" Ад GALANTAMINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE
AT507256B1 (de) * 2008-09-04 2010-10-15 Sanochemia Pharmazeutika Ag Verwendung von galanthaminiumbromid zur herstellung von ophthalmischen formulierungen zur glaukombehandlung
JP2013511990A (ja) 2009-11-26 2013-04-11 クォーク ファーマシューティカルズ インコーポレーティッド 末端置換を含むｓｉＲＮＡ化合物
CA2818024C (fr) 2010-12-06 2019-09-24 Quark Pharmaceuticals, Inc. Composes oligonucleotidiques a double brin comprenant des modifications de position
GB201111319D0 (en) * 2011-07-04 2011-08-17 Univ Leuven Kath Anticonvulsant activity of tumeric oil and bisabolene sesquiterpenoids of curcuma longa
PT3417862T (pt) 2012-07-27 2021-08-06 Neurodyn Life Sciences Inc Biodisponibilidade cerebral da galantamina melhorada através de formulações selecionadas e administração transmucosal de pró-fármacos lipofílicos
WO2014016430A1 (fr) * 2012-07-27 2014-01-30 Neurodyn Life Sciences Inc. Biodisponibilité améliorée de la galantamine dans le cerveau par formulations sélectionnées et administration transmuqueuse de promédicaments lipophiles
CN102788827A (zh) * 2012-09-10 2012-11-21 山东理工大学 一种一步电沉积乙酰胆碱酯酶生物传感器的制备方法
WO2014043291A1 (fr) 2012-09-12 2014-03-20 Quark Pharmaceuticals, Inc. Composés d'acide nucléique double brin
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
WO2015015498A1 (fr) 2013-07-31 2015-02-05 Qbi Enterprises Ltd. Procédés d'utilisation de composés sphingolipide-polyalkylamine-oligonucléotide
WO2015022418A1 (fr) 2013-08-16 2015-02-19 Takeda Gmbh Traitement d'une déficience cognitive à l'aide d'un inhibiteur de pde4
AU2014307802A1 (en) * 2013-08-16 2016-03-10 Universiteit Maastricht Treatment of cognitive impairment with combination therapy
ES2822562T3 (es) * 2014-10-03 2021-05-04 Lachesis Biosciences Ltd Composiciones intranasales para el tratamiento de enfermedades y trastornos neurológicos y degenerativos
MA40998A (fr) 2014-11-21 2017-09-26 Ophirex Inc Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés
WO2016187339A1 (fr) * 2015-05-18 2016-11-24 Synaptec Development Llc Clairance de galantamine d'amyloides
BR122023020807A2 (pt) * 2016-04-12 2023-12-12 Arturo Solis Herrera Uso de agonistas do receptor de acetilcolina nicotínica no tratamento de uma condição de uma membrana mucosa nasal ou paranasal
EP3603649A1 (fr) * 2018-07-31 2020-02-05 Medday Pharmaceuticals Procédé de traitement de maladies à prion
US20220249465A1 (en) * 2019-05-31 2022-08-11 Primo Pharmatech Llc Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient
AU2021309845A1 (en) * 2020-07-14 2023-02-09 Alzheimer's Drug Discovery Foundation Combination drug formulations including rotigotine and an acetylcholinesterase inhibitor for the treatment of neurodegenerative diseases
CU20200087A7 (es) 2020-11-24 2022-07-08 Centro De Neurociencias De Cuba Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer
US12005185B2 (en) * 2021-12-17 2024-06-11 Belhaven BioPharma Inc. Medical counter measures including dry powder formulations and associated methods

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700680A (en) * 1967-10-13 1972-10-24 Dainippon Pharmaceutical Co Aminoalkanol esters and their pharmaceutically acceptable acid-addition salts
US6316439B1 (en) * 1993-10-15 2001-11-13 Aventis Pharamaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US5756480A (en) * 1995-10-26 1998-05-26 Merck & Co., Inc. Treatment of hyperandrogenic conditions
US5830911A (en) * 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
JPH10194996A (ja) * 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物
US6190699B1 (en) * 1998-05-08 2001-02-20 Nzl Corporation Method of incorporating proteins or peptides into a matrix and administration thereof through mucosa
US6369058B1 (en) * 1999-02-04 2002-04-09 New Millennium Pharmaceutical Research Inc. Brain delivery of folic acid for the prevention of alzheimer's disease and stroke
JP2003514564A (ja) * 1999-11-24 2003-04-22 エムシーエス マイクロ キャリア システムズ ゲーエムベーハー 核局在化シグナルまたはタンパク質導入領域の多量体を含むポリペプチド、および分子を細胞内へ移入するためのその使用法
US20040028613A1 (en) * 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
WO2003004600A2 (fr) * 2001-07-05 2003-01-16 Yale University Amelioration de la captation virale dans les cellules et tissus
WO2004034963A2 (fr) * 2002-05-17 2004-04-29 Eisai Co., Ltd. Methodes et compositions utilisant des inhibiteurs de la cholinesterase
US20030225031A1 (en) * 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
JP2005537244A (ja) * 2002-06-28 2005-12-08 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド 療法化合物の粘膜搬送を増進させるための、上皮接合部接着分子の生理機能を調節する組成物および方法
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta

Also Published As

Publication number Publication date
EP1753397A2 (fr) 2007-02-21
US20060003989A1 (en) 2006-01-05
MXPA06012269A (es) 2007-04-25
CA2564353A1 (fr) 2005-11-03
JP2007534686A (ja) 2007-11-29
WO2005102275A3 (fr) 2006-03-30
WO2005102275A2 (fr) 2005-11-03
US20040254146A1 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
WO2005102275B1 (fr) Compositions et procedes d'utilisation d'inhibiteurs d'acetylcholinesterase (ace) pour traiter les troubles du systeme nerveux central chez des mammiferes
JP6505177B2 (ja) 鼻腔内デクスメデトミジン組成物およびその使用方法
US8216604B2 (en) Method of managing or treating pain
EP2574167B1 (fr) Spray nasal liquide contenant du naltrexone à faible dose
JP6574002B2 (ja) 選ばれた処方物によるガランタミンの向上した脳バイオアベイラビリティおよび親油性プロドラッグの経粘膜投与
JP2023076465A (ja) デクスメデトミジン製剤を使用する睡眠障害の予防または治療
WO2011085162A2 (fr) Compositions topiques transdermiques de dexmédétomidine et leurs procédés d'utilisation
KR20120046215A (ko) 소아를 위한 올로파타딘 비강 스프레이 요법
AU2005212355B2 (en) Controlled release formulations
US10925864B2 (en) Stable liquid injectable solution of midazolam and pentazocine
US20230000796A1 (en) Intranasal administration of ketamine to cluster headache patients
CA3145632C (fr) Combinaison d'ibuprofene et de tramadol pour soulager la douleur
EP1734940B1 (fr) Combinaisons de deramciclane et d'opioides destines a l'utilisation analgesique
KR20140145508A (ko) 암브록솔 및 레보드로프로피진을 포함하는 안정성이 개선된 경구용 액상 제제
JP7075708B1 (ja) グリコピロニウム・サリチル酸塩を含む医薬
WO2022168940A1 (fr) Produit pharmaceutique comportant du salicylate de glycopyrronium
Center et al. REVIEW OF INTRANASALLY ADMINISTERED MEDICATIONS FOR USE IN THE EMERGENCY DEPARTMENT
AU2011254554B2 (en) Liquid nasal spray containing low-dose naltrexone
UA113646C2 (xx) Пероральний препарат

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Effective date: 20060220

WWE Wipo information: entry into national phase

Ref document number: 2564353

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007509671

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/012269

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005758604

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005758604

Country of ref document: EP